Cargando…

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

PURPOSE: We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yuanyuan, Zhang, Zicheng, Meng, Qianhao, Wang, Ke, Li, Qingwei, Ma, Yue, Yao, Yuanfei, Sun, Jie, Wang, Guangyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Gastric Cancer Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091457/ https://www.ncbi.nlm.nih.gov/pubmed/35534448 http://dx.doi.org/10.5230/jgc.2022.22.e11

Ejemplares similares

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
por: Yu, Yuanyuan, et al.
Publicado: (2021)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
por: Chen, Jun-Bing, et al.
Publicado: (2022)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
por: Jiang, Zhichao, et al.
Publicado: (2020)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2019)

Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report
por: Lin, Zhixian, et al.
Publicado: (2019)

Construction of Nomogram-Based Prediction Model for Clinical Prognosis of Patients with Stage II and III Colon Cancer Who Underwent Xelox Chemotherapy after Laparoscopic Radical Resection
por: Sun, Qiang, et al.
Publicado: (2022)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
por: Li, Quanfu, et al.
Publicado: (2021)

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
por: Peng, Jianhong, et al.
Publicado: (2020)

Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer
por: Ju, Yeongdon, et al.
Publicado: (2022)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

The prognostic role of fasting plasma glucose levels on survival in advanced colorectal cancer patients with type II diabetes mellitus: a retrospective cohort study
por: Meng, Qianhao, et al.
Publicado: (2022)

Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis
por: Hirata, Fumihiro, et al.
Publicado: (2018)

Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis
por: Li, Yang, et al.
Publicado: (2017)

A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
por: Lee, Guk Jin, et al.
Publicado: (2023)

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
por: Ungari, Andrea Queiróz, et al.
Publicado: (2017)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
por: Hwang, Seung Jae, et al.
Publicado: (2006)

Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer
por: Ohta, Hideki, et al.
Publicado: (2017)

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
por: Chen, Qichen, et al.
Publicado: (2021)

The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis
por: Chen, Wei-Wei, et al.
Publicado: (2022)

A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis
por: Wang, Yan, et al.
Publicado: (2014)

XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
por: Zhu, Xiao‐Dong, et al.
Publicado: (2022)

The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer
por: Zheng, Rong, et al.
Publicado: (2019)

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer
por: YANG, LIN, et al.
Publicado: (2015)

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
por: Peng, Jianhong, et al.
Publicado: (2019)

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
por: Mizushima, Tsunekazu, et al.
Publicado: (2019)

Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis
por: Zhang, Dan, et al.
Publicado: (2018)

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
por: Zhao, Xiao-Yin, et al.
Publicado: (2022)

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
por: Conroy, T, et al.
Publicado: (2010)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
por: Chen, Yizhang, et al.
Publicado: (2023)

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer
por: Yoshida, Yoichiro, et al.
Publicado: (2014)

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
por: Lee, Choong-kun, et al.
Publicado: (2019)

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2019)

Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study
por: Xu, Yan, et al.
Publicado: (2021)

Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study)
por: Aisu, Naoya, et al.
Publicado: (2019)

Prognostic Value of the Lymph Node Ratio in Stage III Gastric Cancer Patients Undergoing Radical Resection
por: Ke, Bin, et al.
Publicado: (2014)

The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial
por: Wang, Xinxin, et al.
Publicado: (2021)

Prognostic effect of excessive chemotherapy cycles for stage II and III gastric cancer patients after D2 + gastrectomy
por: Li, Yi-Fan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qoav54f0sit3kjatrdsi1f3vt9